Gilead wins jury verdict in patent battle with U.S. govt. over HIV therapy
Justin Sullivan/Getty Images News

Gilead Sciences (NASDAQ:GILD) triumphed in a patent dispute related to a HIV treatment on Tuesday after a federal jury in Delaware cleared the company of violating patents held by the Centers for Disease and Prevention (CDC).
The Foster City, California-based biotech was at risk of losing up to $1B in royalties after the U.S. government sued the company in 2019, alleging that it was violating CDC patents linked to Truvada and Descovy, a treatment regimen indicated for HIV prevention.

After a multi-day trial, the jury found that the governmentâs patent claims on the HIV prevention therapy known as pre-exposure prophylaxis, or PrEP were invalid.
âTodayâs decision confirms our longstanding belief that we have always had the rights to make Truvada and Descovy for PrEP available to all who need it,â Deb Telman, Gileadâs (GILD) general counsel, said.

More on Gilead

Gilead slips after cutting 2023 earnings guidance
Gilead Sciences: A Mixed First Quarter